Navigation Links
Researchers find no difference in drugs for macular degeneration
Date:9/30/2010

(Boston) Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is believed to be the first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to ranibizuamab. Last October, these same researchers published early, six month outcomes of the same study, which also failed to show a difference in efficacy between these two drugs for treating AMD.

AMD is the leading cause of blindness over the age of 50 in developed Western countries. It presents in two forms, exudative (wet) or nonexudative (dry). Wet AMD is often more visually devastating with a higher risk of blindness. The gold standard of treatment for wet AMD is ranibizumab (Lucentis, Genentech Inc.), which was FDA approved as an eye injection in 2006. Bevacizumab (Avastin, Genentech Inc.) was FDA approved for the treatment of colorectal cancer in 2004, but has also been used worldwide in an off-label fashion as an eye injection for the treatment of wet AMD. Lucenitis costs approximately $2000.00 per injection, while Avastin costs approximately $50.00 per injection. While both drugs have shown independently to be effective in treating wet AMD, it was uncertain if both drugs were equally efficacious or if either one was better.

In this study, patients were enrolled by a 2:1 ratio to receive either the Avastin or Lucentis. Patients were given eye injections of Avastin or Lucentis every month for the first three months, followed by monthly examination and testing. They received further injections on an as needed basis for one year.

Fifteen patients received Avastin and seven patients received Lucentis. There was no significant difference in visual acuity and anatomic outcomes between the two groups. Both groups had an average improvement in vision of 1.5 lines on the vision testing chart, and only one patient (who was in the Lucentis group) lost a significant amount of vision (three lines or more). In addition, patients in the Avastin group underwent an average of eight injections over one year, while patients in the Lucentis group underwent an average of four injections.

"With the exception that total injections given to subjects over one year were significantly different between the two treatment arms, visual and anatomic outcomes at one year failed to show a significant difference between both groups," said lead author and Principal Investigator Manju Subramanian, MD, an assistant professor in Ophthalmology at BUSM. According to the authors, further studies with larger sample sizes are warranted.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers advance biosynthesis of potent anti-cancer drug Taxol
2. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
3. Researchers at the University of Granada associate trigger points with shoulder injury
4. Researchers to study effects of Mass. health reform
5. IU researchers: Chemotherapy alters brain tissue in breast cancer patients
6. Researchers use CT to predict heart disease
7. VCU study: Researchers discover a drug combination that shrinks tumors in vivo
8. Sugary sports drinks mistakenly associated with being healthy, say UTHealth researchers
9. Researchers create first molecule blocks key component of cancer genes on-off switch
10. Researchers create first molecule-blocks key component of cancer genes on-off switch
11. Team of researchers finds possible new genetic risk for Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology: